AbbVie or Bristol-Myers Squibb: Better Healthcare Stock for 2026?

Comparing Pharmaceutical Titans: AbbVie and Bristol-Myers Squibb

When it comes to choosing between investing in AbbVie (ABBV -0.54%) or Bristol-Myers Squibb (BMY -1.27%), potential investors must consider a variety of factors. Both pharmaceutical companies have key assets in the high-growth immunology field and offer extensive value, yet also face challenges in the form of patent expirations and potential drug pricing reforms.

AbbVie vs Bristol-Myers Squibb: The Landscape

Specialising in specialty immunology and aesthetics, AbbVie is transitioning away from its dependence on its Humira product line. On the other hand, Bristol-Myers Squibb focuses on oncology and cardiovascular health, pushing towards its next-generation pipeline. As substantial contributors to the pharmaceutical industry, both companies offer consistent dividends and stable cash flows, making them attractive to income-focused investors.

Financial Performance of AbbVie and Bristol-Myers Squibb

AbbVie is an international biopharmaceutical company that provides innovative medicines to approximately 180 countries. It operates manufacturing facilities in around 20 countries, with primary U.S. sales being driven by three major wholesale distributors – McKesson Corporation, Cardinal Health, and Cencora. Despite this, no single wholesaler made up more than 43% of total U.S. gross revenues in 2025. In Fiscal Year (FY) 2025, AbbVie recorded revenues of about $61.2 billion, marking an 8.6% growth from the previous year. This was largely attributed to the expansion of their newer drug labels counteracting the revenue erosion from older products.

Meanwhile, Bristol-Myers Squibb is a global biopharmaceutical leader focusing on serious diseases in oncology, hematology, and cardiovascular health. Despite a slight decrease in revenue by 0.2% to $48.2 billion in FY 2025, the company realised a net income of approximately $7.1 billion. This significant recovery from the prior year’s net loss was largely due to specific one-time charges.

Risk Factors for AbbVie and Bristol-Myers Squibb

AbbVie faces potential risks from patent expiry and the rise in competition for key immunology drugs. Furthermore, the company may be impacted by possible pricing pressures from the Inflation Reduction Act, which allows for government regulation of product prices. The company also continues to compete with Pfizer in the specialty medicine market.

On the other hand, Bristol-Myers Squibb faces expected losses of market exclusivity for blockbuster drugs like Eliquis and Opdivo, which could lead to substantial revenue declines. The company also contends with global pricing and reimbursement restrictions, decreased pricing flexibility, and dependence on the continuous flow of new products. Any setbacks in clinical trials or regulatory delays could harm long-term growth. Bristol-Myers Squibb also competes with Merck in the highly competitive oncology space.

Projecting Future Value: AbbVie vs Bristol-Myers Squibb

While Bristol-Myers Squibb has a lower Forward P/E and P/S ratio than AbbVie, hinting at a slower growth expectation, it’s also essential to consider other factors.

The Investment Choice for 2026: AbbVie or Bristol-Myers Squibb?

Both companies present valuable investment opportunities, with Bristol-Myers Squibb showcasing progress with newer growth brands and a promising pipeline. However, the company still contends with a patent cliff expected to impact revenue negatively in the near future. Additionally, potential drug pricing reforms create an added layer of uncertainty.

Conversely, AbbVie is maintaining a more focused strategy and delivering impressive results. The company’s neuroscience portfolio is accelerating growth, and with Humira biosimilar competition now mostly past, prospects look promising. Moreover, AbbVie recently raised its full-year outlook for the second time this year and offers one of the most enticing dividends in healthcare.

Therefore, considering the current growth trajectory and dividend yield, AbbVie could be the stronger pick for long-term investors at this time.